Home news Chemotherapy Induced Neutropenia Market Insights 2017 to 2023

Chemotherapy Induced Neutropenia Market Insights 2017 to 2023

95
SHARE

DM’s “Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology
and Market Forecast-2023” Report provides an overview of the disease and global market
trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United
States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE)
and rest of the world (RoW). The Report covers the therapeutics market revenue, treatment
practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to
2023 segmented by seven major markets. In addition, the report provides the historical and
forecasted of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 cancer
indications till 2023.

The report covers the number of patients for 10 cancer indications (i.e., Breast Cancer,
Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer,
Ovarian Cancer, Hodgkin’s disease and Non-Hodgkin Lymphoma), who are at risk of developing
CIN as an adverse event of the chemotherapies of respective cancers.

Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for
chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was
later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute
to majority of the market size, of CIN. However, New Chemical Entities are expected to launch
in the near future. According to DM, the worldwide CIN market is estimated to
increase at a CAGR of 3.37% for the forecast period i.e., 2013-2023.

The report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Request for a Demo Report at: https://www.diligentmarket.com/request-sample-page.php?gturl=13435

Scope of this report: The report provides competitive pipeline landscape of Chemotherapy Induced Neutropenia (CIN). The report provides the marketed drugs information including its sales, development activities and details of patent expiry. The report provides the insight of current and future market for Chemotherapy Induced Neutropenia (CIN). The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information. Coverage of the Chemotherapy Induced Neutropenia (CIN) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type. The report reviews key players involved in the therapeutics development for Chemotherapy Induced Neutropenia (CIN) and also provide company profiling. The report also gives the information of dormant pipeline projects. Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages and Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Business insights delivered by this report are:-

  1. Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
  2. Complete MOA intelligence and complete understanding over therapeutics development for Chemotherapy Induced Neutropenia (CIN)
  3. Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
  4. Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (CIN) pipeline depth and focus of Indication therapeutics
  5. Developing strategic initiatives to support your drug development activities.
  6. Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  7. Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  8. Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  9. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
  10. Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Browse Full Report at: https://www.diligentmarket.com/chemotherapy-induced-neutropenia-cin-market-insights-epidemiology-and-market-forecast-2023-13435-p.php

Key Coverage and Benefits

The report will help in developing business strategies by understanding the trends shaping and driving the global Chemotherapy Induced Neutropenia (CIN) market.

Identifying prevalent patient populations as well as risk factors in the global Chemotherapy Induced Neutropenia (CIN) market will help to improve product design, pricing, and launch plans

To understand the current pipeline scenario of different companies so as to make the Research activity more robust and competitive.

To understand the future market competition in the global Chemotherapy Induced Neutropenia (CIN) market And Insightful review of the key market drivers and barriers

The report also covers the detailed global historical and forecasted Chemotherapy Induced Neutropenia (CIN)

Market covering United States, European Union 5 (EU5 – Germany, Spain, Italy, France

And United Kingdom) and Japan from 2013-2025

Essential Points Covered in Table of Contain

Report Introduction

Executive Summary Snapshot

Market Drivers

Market Barriers

SWOT Analysis

Report Methodology

Consulting Services

Collaborations & Deal Value Trends

Companies collaborations for future developments

List of Figures are

Companies Collaborations vs. Financial year, 2017

Number of Companies Collaborations, 2017

Collaborations and Upfront Deal Values (In million, $), 2017

Number of Products under Development, 2017

Number of Products under Development by Companies, 2017

Number of Products under Development by Indication, 2017

About us:

DiligentMarket is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses.

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.

The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing cutting-edge market and pipeline information, to our clients.

Connect With us on:

+91-750 707 8687

sales@diligentmarket.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here